Anti-Human VEGF Recombinant Antibody (Bevacizumab)
Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. Bevacizumab is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A).
Anti-Human VEGF Recombinant Antibody (Bevacizumab)
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Recombinant monoclonal antibody to Human VEGF is an angiogenesis inhibitor, a drug that slows the growth of new blood vessels. It is licensed to treat various cancers, including colorectal, lung, breast (outside the USA), glioblastoma (USA only), kidney, and ovarian. Bevacizumab is a humanized monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). VEGF-A is a chemical signal that stimulates angiogenesis in a variety of diseases, especially in cancer. It is designed to support reliable, reproducible results in modern laboratories. It helps streamline your workflow, reduce troubleshooting, and deliver consistent performance across batches. Prominent attributes include productname and abbr.
Manufactured under rigorous quality controls, each lot is checked for key specifications to ensure lot‑to‑lot consistency. The format is optimized for ease of use and integration into existing protocols, with documentation available upon request.
Key Features / Benefits
- productname: Anti-Human VEGF Recombinant Antibody (Bevacizumab)
- abbr: Bevacizumab
- Target: VEGFA
- Host Animal: Mouse
- Specificity: Tested positive against native human antigen
- Immunogen: Purified intact human VEGF
Relevant Applications
- Suitable for use in FC
- IP
- ELISA
- Neut
- FuncS
- IF
- ICC and most other immunological methods.
